216 related articles for article (PubMed ID: 10928158)
1. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
[TBL] [Abstract][Full Text] [Related]
2. Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation.
Uchiyama B; Saijo Y; Kumano N; Abe T; Fujimura S; Ohkuda K; Handa M; Satoh K; Nukiwa T
Clin Cancer Res; 1997 Oct; 3(10):1873-7. PubMed ID: 9815576
[TBL] [Abstract][Full Text] [Related]
3. Pathology of non-small cell lung cancer. New diagnostic approaches.
Linnoila I
Hematol Oncol Clin North Am; 1990 Dec; 4(6):1027-51. PubMed ID: 1962774
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung cancer.
Chyczewski L; Nikliński J; Chyczewska E; Laudański J; Furman M
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():162-72. PubMed ID: 9337534
[TBL] [Abstract][Full Text] [Related]
5. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
8. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
9. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
10. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
12. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
[TBL] [Abstract][Full Text] [Related]
13. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
14. [The prognostic value of cytokeratin 19 expression in non-small cell lung cancer].
Kosacka M; Jankowska R
Pneumonol Alergol Pol; 2007; 75(4):317-23. PubMed ID: 18080980
[TBL] [Abstract][Full Text] [Related]
15. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
Komiya T; Hosono Y; Hirashima T; Masuda N; Yasumitsu T; Nakagawa K; Kikui M; Ohno A; Fukuoka M; Kawase I
Clin Cancer Res; 1997 Oct; 3(10):1831-5. PubMed ID: 9815570
[TBL] [Abstract][Full Text] [Related]
16. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
[TBL] [Abstract][Full Text] [Related]
18. Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas.
Dobashi Y; Watanabe H; Sato Y; Hirashima S; Yanagawa T; Matsubara H; Ooi A
J Pathol; 2006 Dec; 210(4):431-40. PubMed ID: 17029220
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.
Koutsopoulos AV; Mavroudis D; Dambaki KI; Souglakos J; Tzortzaki EG; Drositis J; Delides GS; Georgoulias V; Stathopoulos EN
Lung Cancer; 2007 Aug; 57(2):193-200. PubMed ID: 17442448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
